;

EcoVadis assessment

Teva awarded an EcoVadis Silver Medal for Corporate Social Responsibility

[11-09-2019]

Healthcare is a global priority that affects each and every one of us. At Teva api, within Teva Pharmaceuticals, we are dedicated to leveraging our corporate resources and expertise to promote healthy communities all over the world. Our ambitious, wide-ranging social impact activities recently won us an EcoVadis Silver Medal, reflecting our ongoing efforts to cultivate responsible business practices and positive social initiatives.

Teva api is a leading international supplier of quality active pharmaceutical ingredients, with the industry’s broadest portfolio of more than 400 API products. We support 75% of the top 50 global pharmaceutical companies via 17 manufacturing plants, five R&D centers, and seven sales offices, accumulating an annual $745.5M in sales. Serving nearly 1,100 customers in more than 75 countries, we are profoundly aware of our deep responsibility to not only comply with all applicable laws and regulations, but also actively work to exert a positive effect on the world around us. With this in mind, we are delighted to present the Teva 2018 Social Impact Report, which clearly illustrates our steadfast commitment to patients and communities everywhere. For a brief overview of the report's highlights, see the short video below:

http://bit.ly/2NJqPsF

Teva was awarded an EcoVadis Silver Medal for responsible conduct in environment, labor and human rights practices, ethics and sustainable procurement in 2018 – a score placing us in the top 16% of all pharmaceutical companies. EcoVadis is the world's most trusted provider of business sustainability ratings for global supply chains, with its famous scorecards providing invaluable, detailed insight into environmental, social, and ethical factors. Receiving the EcoVadis Silver Medal is not only a huge honor for Teva and Teva api, but also confirmation that we are meeting our ambitious performance, quality, and social impact goals.

Quality API

As generics play an increasingly significant role in global healthcare, questions are continually being raised about product quality. Are these affordable alternatives actually as safe and effective as their brand-name counterparts? Throughout the business landscape, and particularly where health is concerned, customers want to deal with companies that not only supply reliably high-quality products, but also behave in a socially-responsible manner and have a positive impact on the environment.

Teva and Teva api exemplify the very best in both product quality and responsible citizenship. Our mission to improve patient lives and promote global health always comes first, empowering our dedication to absolute product quality and safety. Some 200 million people take our medicines daily, and we carefully monitor all our products throughout their entire lifecycle via our pharmacovigilance division, in strict compliance with global regulations. In 2018, we gained approvals for 900+ generics, helping to make treatments more affordable. We also achieved significant improvements in safety management and environmental sustainability, while launching unique social impact activities that are driving meaningful change in communities worldwide – two of which are briefly described below.

Access to Medicines

Even the best, most effective medications become useless if patients have no way to access them. Although generics have revolutionized healthcare for millions of patients around the globe, dramatically reducing costs across the board, the World Health Organization (WHO) estimates that more than 50% of people still lack access to critical health services. As the world’s leading provider of generic medicines, we continually strive to improve disadvantaged populations' access to quality healthcare and medicines, including those on the WHO's Essential Medicines List, and expand our generics pipeline.

We recognize that healthcare access is a complex global issue that can only be addressed through diverse, sustained efforts that actively engage governments, NGOs, humanitarian organizations, healthcare professionals, and pharmaceutical companies in cross-sector partnerships. In 2018, Teva donated more than $380M worth of medicines to patients around the world and supplied 220,000 packs of antibiotics and 1.5 million packs of vitamin B6 for patients with tuberculosis. Although there is a long road ahead, these actions make a real difference to so many lives.

Multiple Chronic Conditions (MCC) Initiative

Since 2017, Teva has been championing better understanding, treatment, and prevention of non-communicable diseases by addressing the issue of multiple chronic conditions (MCC). MCC affects 1 in 3 adults and two thirds of seniors (65+) worldwide. In older adults, each additional chronic condition can mean being prescribed as many as 8 more medications, more than doubling healthcare costs and lowering patient adherence. There is a pressing need to simplify medication regimens while adopting a holistic, patient-centric approach to managing multiple conditions.

MCC is a concern close to Teva's heart, as we produce many medicines to treat chronic conditions, and recognize that current research and healthcare infrastructures are not sufficient to handle the global burden of chronic disease, which falls disproportionately on low-income countries. In order to improve quality of life for patients and caregivers around the globe, we are working closely with Mount Sinai’s Arnhold Institute for Global Health, independent researchers, healthcare leaders, and patient organizations to raise awareness of MCC's considerable social impact, understand patient needs, and identify patient-centered solutions.

Social Impact for 2019 & Beyond

As our 2018 Social Impact Report describes, Teva and its pharmaceutical ingredients division, Teva api, have made great strides forward in endorsing meaningful social initiatives and research dedicated to improving the health of underserved communities worldwide. However, we also recognize that this is an ongoing process. Looking toward the future, Amalia Adler-Waxman, Vice President, Social Impact & Responsibility, said:

"I’m most excited to continue serving patients by developing new treatment options, reaching more patients with our medicines, supporting patients on their health journeys and contributing to their overall health. And beyond that, I’m excited about the role we can play in addressing global health issues through unique partnerships."

Read more of our conversation with Amalia here for greater insight into Teva's social impact initiatives and our goals for the future. The potential to make a difference is truly limitless.

EcoVadis assessment